Physician

John D. Sprandio, MD

According to 2025 Medicare claims, John Sprandio, MD (NPI: 1487819769) practices hematology/oncology in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Delaware, PA. This provider's primary affiliated billing organization is CONSULTANTS IN MEDICAL ONCOLOGY & HEMATOLOGY, PC (NPI: 1043265820; TIN: 23-2826618) and primary practice location at 19008-3301.

Sprandio's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 660 traditional Medicare patients, billed 196,729 HCPCS/CPT codes, and received $2,896,177 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,446 prescription claims across 253 beneficiaries totaling $2,487,672 in drug costs, led by Revlimid (Lenalidomide). DME data shows 12 claims. Open Payments data shows 102 records totaling $19,545. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,544,957 to $2,896,177. Similarly, Part D prescription costs have moved sharply higher in recent years, from $171,492 to $2,487,672. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $1,476 to $875.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	478	186,206	$1,544,957
2016	518	90,562	$1,132,389
2017	449	87,766	$899,834
2018	462	112,854	$1,117,976
2019	446	126,831	$1,547,034
2020	497	142,310	$1,647,219
2021	532	192,167	$1,988,937
2022	527	196,448	$2,241,643
2023	568	185,250	$2,499,090
2024	660	196,729	$2,896,177

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	113	569	$171,492
2016	136	862	$370,099
2017	143	876	$500,354
2018	144	978	$503,612
2019	162	1,136	$1,070,825
2020	149	953	$1,151,885
2021	207	1,313	$1,737,610
2022	212	1,304	$1,673,819
2023	214	1,319	$2,586,154
2024	253	1,446	$2,487,672

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	30	$10,063
2016	N/R	N/R	N/R
2017	N/R	11	$207
2018	N/R	N/R	N/R
2019	N/R	35	$3,934
2020	N/R	N/R	N/R
2021	N/R	41	$1,157
2022	N/R	N/R	N/R
2023	N/R	46	$3,784
2024	N/R	12	$168

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	327	978	$142
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	329	551	$96
96372	Injection of drug or substance under skin or into muscle	131	595	$11
36415	Insertion of needle into vein for collection of blood sample	458	1,258	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	509	1,513	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	16	448	$294,014
Calquence	Acalabrutinib Maleate	17	510	$255,377
Verzenio	Abemaciclib	13	476	$252,532
Jakafi	Ruxolitinib Phosphate	12	360	$201,271
Monjuvi	Tafasitamab-Cxix	24	378	$179,424

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	12	$168

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	94	$2,292	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	8	$17,253	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John D. Sprandio, MD?

Tedicare shows public-source Medicare data for John D. Sprandio, MD (NPI 1487819769), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John D. Sprandio, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John D. Sprandio, MD?

John D. Sprandio, MD is linked to CONSULTANTS IN MEDICAL ONCOLOGY & HEMATOLOGY, PC (billing NPI 1043265820) in the available physician profile data.

Does John D. Sprandio, MD have Open Payments data?

John D. Sprandio, MD has 102 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.